ITeos Therapeutics Q3 EPS $(0.90) Beats $(1.20) Estimate; Cash, Cash Equivalents, And Investments Position Was $644.9M Expected To Provide Runway Through 2026
Portfolio Pulse from Benzinga Newsdesk
ITeos Therapeutics reported Q3 losses of $(0.90) per share, beating the analyst consensus estimate of $(1.20) by 25 percent. This represents a 3100 percent decrease over earnings of $0.03 per share from the same period last year. The company's cash, cash equivalents, and investments position was $644.9M, expected to provide runway through 2026.
November 07, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ITeos Therapeutics reported better than expected Q3 losses and has a strong cash position expected to last through 2026.
ITeos Therapeutics reported a smaller loss than expected, which is generally seen as positive by the market. Additionally, the company's strong cash position provides financial stability and reduces the risk of liquidity issues in the near future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100